ArticleSurgical case reports2026
A Shared Genomic Alteration Supported the Diagnosis of Two Tumors in the Remnant Pancreas 7 Years after Resection of Distal Cholangiocarcinoma.
Article in Surgical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMetastatic tumors to the pancreas account for approximately 2% of all pancreatic malignancies, and pancreatic metastasis from distal cholangiocarcinoma is extremely rare. Differentiating pancreatic metastasis of cholangiocarcinoma from primary pancreatic cancer is often difficult, as both typically present as adenocarcinoma with similar immunohistochemical features. CASE PRESENTATION: A 65-year-old man underwent subtotal stomach-preserving pancreatoduodenectomy (SSPPD) for distal cholangiocarcinoma. He was diagnosed with pT3N0M0, Stage IIB according to the UICC TNM classification, 8th edition. Seven years after surgery, a routine blood test revealed an elevated serum carbohydrate antigen 19-9 level. Abdominal MRI and CT demonstrated 2 small masses, each approximately 10 mm in diameter, in the remnant pancreas without evidence of distant metastasis. Both lesions were diagnosed as adenocarcinoma by endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA), suggesting either pancreatic metastases from distal cholangiocarcinoma or primary pancreatic cancer in the remnant pancreas. Completion total pancreatectomy with splenectomy was therefore performed. Histopathological examination showed that both lesions in the remnant pancreatic tail were morphologically similar to the initial cholangiocarcinoma. However, the possibility of primary pancreatic cancer could not be completely excluded. Comprehensive genomic profiling (CGP) of the initial cholangiocarcinoma and the remnant pancreatic tumor revealed a shared
conclusionsWe report a rare case of multiple pancreatic metastases occurring 7 years after resection of distal cholangiocarcinoma. Evaluation of genetic alterations provided supportive evidence to aid in distinguishing metastatic disease from primary pancreatic cancer in the remnant pancreas. In addition, these findings also suggested potentially relevant therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.